Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more
Aptorum Group Ltd Class A (APM) - Total Assets
Latest total assets as of September 2025: $18.10 Million USD
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) holds total assets worth $18.10 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aptorum Group Ltd Class A - Total Assets Trend (2016–2024)
This chart illustrates how Aptorum Group Ltd Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aptorum Group Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Aptorum Group Ltd Class A's total assets of $18.10 Million consist of 6.0% current assets and 94.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.4% |
| Accounts Receivable | $4.54K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Aptorum Group Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aptorum Group Ltd Class A's current assets represent 6.0% of total assets in 2024, an increase from 1.6% in 2016.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Aptorum Group Ltd Class A Competitors by Total Assets
Key competitors of Aptorum Group Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Aptorum Group Ltd Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aptorum Group Ltd Class A generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aptorum Group Ltd Class A is currently not profitable relative to its asset base.
Aptorum Group Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.98 | 1.17 | 8.70 |
| Quick Ratio | 2.98 | 1.17 | 8.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.00 Million | $ 217.54K | $ 29.79 Million |
Aptorum Group Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Aptorum Group Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.29 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -21.9% |
| Total Assets | $16.13 Million |
| Market Capitalization | $3.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aptorum Group Ltd Class A's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aptorum Group Ltd Class A's assets decreased by 21.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aptorum Group Ltd Class A (2016–2024)
The table below shows the annual total assets of Aptorum Group Ltd Class A from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $16.13 Million | -21.85% |
| 2023-12-31 | $20.64 Million | -1.09% |
| 2022-12-31 | $20.87 Million | -4.75% |
| 2021-12-31 | $21.91 Million | -50.47% |
| 2020-12-31 | $44.23 Million | +84.65% |
| 2019-12-31 | $23.95 Million | -46.86% |
| 2018-12-31 | $45.07 Million | +42.82% |
| 2017-12-31 | $31.56 Million | +24.33% |
| 2016-12-31 | $25.38 Million | -- |